Crossmark

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Crossref DOI link: https://doi.org/10.1186/s12885-018-5167-y

Published Online: 2018-12-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cerveira, Nuno http://orcid.org/0000-0001-5098-3840
Loureiro, Bruno

Bizarro, Susana

Correia, Cecília

Torres, Lurdes

Lisboa, Susana

Vieira, Joana

Santos, Rui

Pereira, Dulcineia

Moreira, Cláudia

Chacim, Sérgio

Domingues, Nélson

Espírito-Santo, Ana

Oliveira, Isabel

Moreira, Ilídia

Viterbo, Luísa

Martins, Ângelo

Teixeira, Manuel R.

Mariz, José M.
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 12 July 2018

Accepted: 30 November 2018

First Online: 12 December 2018

Ethics approval and consent to participate

: This study is in accordance with the ethical standards of the Ethics Committee of the Portuguese Oncology Institute of Porto and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed verbal consent was obtained from all human subjects and registered in the clinical record according with the approved institutional protocol for the management of patients with chronic myeloid leukemia of the Portuguese Oncology Institute of Porto.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.